(Q33396181)

26 July 2017

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma (English)

1 reference

26 July 2017

1 reference

April Coan

3

0 references

Henry Seth Friedman

series ordinal

10

object named as

Henry S Friedman

1 reference

26 July 2017

6

Sridharan Gururangan

1 reference

26 July 2017

4

Annick Desjardins

1 reference

26 July 2017

1

David A Reardon

1 reference

26 July 2017

8

Jeremy N Rich

1 reference

26 July 2017

2

James J Vredenburgh

1 reference

26 July 2017

5

Katherine B Peters

1 reference

26 July 2017

7

Sith Sathornsumetee

1 reference

26 July 2017

9

James E Herndon

1 reference

26 July 2017

9 July 2011

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

105

1 reference

26 July 2017

3

1 reference

26 July 2017

621-627

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-011-0631-4

26 July 2017

0 references

cites work

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Tumor angiogenesis: a quantitative method for histologic grading.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

14 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0631-4

Brain metastasis in renal cell cancer responding to sunitinib.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748953

10.1007/S11060-011-0631-4

31 October 2018

Identifiers

DOI

1 reference

PubMed ID

21744079

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference

PubMed ID

21744079